Malaria Rapid Diagnostic Test: A Flawed Tool in the Fight Against Malaria?
A recent international study has raised concerns about the accuracy of a widely used rapid diagnostic test for malaria, highlighting its potential to deliver false-negative results and misdiagnose patients. The Abbott-Bioline rapid diagnostic test, deployed in Southeast Asia, has been found to have significantly lower sensitivity rates compared to other brands, with only 18% of Plasmodium falciparum and 44% of Plasmodium vivax infections correctly identified. This alarming finding has sparked calls for the test's removal from the market in the region, where malaria affects around 4 million people annually.
The study, conducted by researchers from the Shoklo Malaria Research Unit (SMRU) in collaboration with Oxford University's MORU Tropical Health Network, compared the Abbott-Bioline test with other rapid diagnostic tests and microscopy. The results revealed that many tests produced faint lines, even in cases where patients exhibited clear signs of fever, leading to potential misdiagnosis. This issue is particularly concerning in remote areas where laboratory testing is limited.
Despite the study's findings, Abbott Diagnostics, the manufacturer, claims that the tests are functioning as intended and provides evidence of their accuracy through multiple published studies. However, critics argue that faint lines increase the risk of misinterpretation and misrecording of test results, which can have severe consequences in malaria-prone regions.
The World Health Organization (WHO) has acknowledged the issue, reviewing reports of false negatives and faint positive test lines since August 2024. They have issued public notices and technical notes to ensure proper test usage and increase incident reporting. The WHO is also working with Abbott Diagnostics Korea to address concerns, but the manufacturer's product remains on the market for now.
The study's implications are significant, as rapid diagnostic tests are crucial for malaria control, enabling quick and efficient treatment even in remote areas. However, the Abbott-Bioline test's limitations raise questions about the reliability of malaria diagnosis in certain regions, potentially impacting the effectiveness of global malaria control efforts.
